As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with first-line therapies offering limited survival benefits despite advances ...

The FDA has approved trastuzumab deruxtecan (T-DXd; Enhertu, Daiichi Sankyo/AstraZeneca) in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast ...

What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...

Treatment with T-DXd resulted in a statistically significant and clinically meaningful improvement in IDFS vs T-DM1. Topline results were announced from a phase 3 trial comparing fam-trastuzumab ...